Showing 1 - 12 results of 12 for search 'Kim A Papp', query time: 0.04s
Refine Results
-
1
-
2
Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of hea... by Andreas Pinter, Kilian Eyerich, Antonio Costanzo, Alyssa Garrelts, Christopher Schuster, Can Mert, Anastasia Lampropoulou, Konstantinos Fotiou, Julia-Tatjana Maul, Kim A. Papp
Published 2024-12-01
Article -
3
Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation Analysis by April W. Armstrong, Peter Foley, Yan Liu, Megan Miller, Rachel E. Teneralli, Anthony Bewley, Kenneth B. Gordon, Kim A. Papp, Chenglong Han
Published 2024-08-01
Article -
4
Correction to: Qualitative Assessment of Adult Patients’ Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional Study by Bruno Falissard, Eric L. Simpson, Emma Guttman-Yassky, Kim A. Papp, Sebastien Barbarot, Abhijit Gadkari, Grece Saba, Laurene Gautier, Adeline Abbe, Laurent Eckert
Published 2020-03-01
Article -
5
Qualitative Assessment of Adult Patients’ Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional Study by Bruno Falissard, Eric L. Simpson, Emma Guttman-Yassky, Kim A. Papp, Sebastien Barbarot, Abhijit Gadkari, Grece Saba, Laurene Gautier, Adeline Abbe, Laurent Eckert
Published 2020-01-01
Article -
6
-
7
Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy by Andrew Blauvelt, Richard G. Langley, Patrick J. Branigan, Xuejun Liu, Yanqing Chen, Samuel DePrimo, Keying Ma, Brittney Scott, Kim Campbell, Ernesto J. Muñoz-Elías, Kim A. Papp
Published 2024-09-01
Article -
8
Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials by Kenneth B. Gordon, Andrew Blauvelt, Hervé Bachelez, Laura C. Coates, Filip E. Van den Bosch, Blair Kaplan, Willem Koetse, Doug G. Ashley, Ralph Lippe, Ranjeeta Sinvhal, Kim A. Papp
Published 2024-08-01
Article -
9
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials by April W. Armstrong, Matthias Augustin, Jennifer L. Beaumont, Tan P. Pham, Stacie Hudgens, Kenneth B. Gordon, Joe Zhuo, Brandon Becker, Yichen Zhong, Renata M. Kisa, Subhashis Banerjee, Kim A. Papp
Published 2024-07-01
Article -
10
Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 ... by Diamant Thaçi, Mamitaro Ohtsuki, Julia-Tatjana Maul, Andrea Szegedi, Paula C. Luna, Charles W. Lynde, Ahmed M. Soliman, Hongwei Wang, Christian Kaufmann, Doug G. Ashley, Tshepiso Madihlaba, Simone Rubant, Kim A. Papp
Published 2025-02-01
Article -
11
Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular Events by Mark Lebwohl, Atul Deodhar, Sergio Schwartzman, Carlo Salvarani, Meghan Feely McDonald, Natalia Bello, Elsie L. Grace, Elsa Inman, Andris Kronbergs, Marcus Ngantcha, Proton Rahman, Kim A. Papp, Joseph F. Merola, Alice B. Gottlieb, Andrew Blauvelt
Published 2025-01-01
Article -
12
Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trial... by Atul Deodhar, Andrew Blauvelt, Mark Lebwohl, Meghan Feely, Andris Kronbergs, Nadezhda Eberhart, Danting Zhu, Elsa Inman, Elsie Grace, Thorsten Holzkaemper, Proton Rahman, Helena Marzo-Ortega, Kim A. Papp, Joseph F. Merola, Alice B. Gottlieb, Sergio Schwartzman
Published 2024-02-01
Article